{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:20:39Z","timestamp":1769044839491,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jbspin.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:49:16Z","timestamp":1536324556000},"page":"321-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted immunotherapy strategies in ANCA-associated vasculitis"],"prefix":"10.1016","volume":"86","author":[{"given":"Xavier","family":"Pu\u00e9chal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.09.002_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with anti-neutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0010","unstructured":"http:\/\/www.has-sante.fr\/portail\/plugins\/ModuleXitiKLEE\/types\/FileDocument\/doXiti.jsp?id=c_608140."},{"key":"10.1016\/j.jbspin.2018.09.002_bib0015","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener\u2019s) or microscopic polyangiitis","volume":"68","author":"Pu\u00e9cha","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaut.2005.08.004","article-title":"BAFF is elevated in the serum of patients with Wegener\u2019s granulomatosis","volume":"25","author":"Krumbholz","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0045","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0091-6749(99)70434-3","article-title":"Differential B and T-cell activation in Wegener\u2019s granulomatosis","volume":"103","author":"Popa","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1196\/annals.1361.042","article-title":"Is PR3-ANCA formation initiated in Wegener\u2019s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production","volume":"1051","author":"Voswinkel","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2005.044909","article-title":"B lymphocyte maturation in Wegener\u2019s granulomatosis: a comparative analysis of VH genes from endonasal lesions","volume":"65","author":"Voswinkel","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of anti-neutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0065","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1136\/ard.2011.153890","article-title":"ANCA-stimulated neutrophils release BLyS and promote B-cell survival: a clinically relevant cellular process","volume":"70","author":"Holden","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0070","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/rheumatology\/ker150","article-title":"Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"51","author":"Guerry","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0075","unstructured":"http:\/\/www.cri-net.com\/recherche\/fichesPratiques\/get_fiche.asp?lang=rituximab&chap=19_Utilisation_du_rituximab_dans_les_maladies_auto-immunes."},{"key":"10.1016\/j.jbspin.2018.09.002_bib0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0095","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0100","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0110","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0115","first-page":"18L","article-title":"Rituximab as re-induction therapy in relapsing ANCA-associated vasculitis [abstract]","volume":"69","author":"Smith","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0120","article-title":"Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients","author":"Pu\u00e9chal","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0125","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing ANCA-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0130","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/art.38744","article-title":"Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener\u2019s): a retrospective single-center study","volume":"66","author":"Azar","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"For the French Vasculitis Study Group (FVSG): rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0140","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0145","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): a single-center ten-year experience","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0150","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0155","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","article-title":"Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, anti-neutrophil cytoplasm antibody-associated necrotizing vasculitides","volume":"42","author":"Charles","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0160","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0165","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0170","first-page":"62","article-title":"Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)","volume":"28","author":"Schneeweis","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0175","first-page":"893","article-title":"Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: a multicenter randomized, placebo-controlled study [abstract]","volume":"69","author":"Jayne","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0180","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","article-title":"Anti-neutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo","volume":"104","author":"Pfister","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.1990.tb03336.x","article-title":"Enhanced expression of the tumour necrosis factor\/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis","volume":"81","author":"Deguchi","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0190","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2249.1994.tb06518.x","article-title":"Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo","volume":"95","author":"Csernok","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0195","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","article-title":"In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis","volume":"43","author":"Noronha","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jbspin.2012.10.023","article-title":"Therapeutic immunomodulation in systemic vasculitis: taking stock","volume":"80","author":"Pu\u00e9chal","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0205","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: long-term follow-up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Q J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0220","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with anti-neutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0225","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0230","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/0140-6736(93)90759-A","article-title":"Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy","volume":"1","author":"Lockwood","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0235","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0240","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","article-title":"Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Emmi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0245","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg\u2013Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0260","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrrheum.2017.117","article-title":"Vasculitis: mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"13","author":"Guillevin","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0265","first-page":"256","article-title":"Perspectives de traitement par biom\u00e9dicaments dans la granulomatose \u00e9osinophilique avec polyang\u00e9ite (Churg\u2013Strauss)","volume":"84","author":"Pu\u00e9chal","year":"2017","journal-title":"Revue Rhum"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0270","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejim.2007.09.001","article-title":"Churg\u2013Strauss syndrome associated with omalizumab","volume":"19","author":"Pu\u00e9chal","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0275","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): data on seventeen patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0280","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","article-title":"Interferon-alpha treatment of four patients with the Churg-Strauss syndrome","volume":"129","author":"Tatsis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0285","first-page":"S35","article-title":"A phase II study of interferon-alpha for the treatment of refractory Churg\u2013Strauss syndrome","volume":"26","author":"Metzler","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0290","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/ard.2004.032664","article-title":"Leucoencephalopathy after treatment of Churg\u2013Strauss syndrome with interferon alpha","volume":"64","author":"Metzler","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.09.002_bib0295","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1078\/0171-2985-00197","article-title":"Treatment of refractory Churg\u2013Strauss syndrome (CSS) by TNF-alpha blockade","volume":"206","author":"Arbach","year":"2002","journal-title":"Immunobiology"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18302859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18302859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:25Z","timestamp":1761150325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X18302859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1297319X18302859"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.09.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted immunotherapy strategies in ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}